Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TVF Communications

- PMLiVE

Sage raises $575m ahead of FDA review date for Zulresso

Company should get verdict by 19 March

- PMLiVE

EMA could follow FDA’s Xeljanz blood clot warning

European agency in step with FDA after safety doubts

Bluedog Launch Celebrations

Teams from all companies within the Lucid Group and Bluedog gathered to celebrate both the launch of this new partnership and Lucid Group’s twelve-year anniversary.  2019 is set to be a...

Lucid Group Communications Limited

- PMLiVE

Rare Disease Day 2019: A patient perspective on primary sclerosing cholangitis

An interview with Debbie, office manager at Porterhouse Medical, on what it’s like to live with the rare disease, PSC. Read more ...

Porterhouse Medical Group

Statistics and Infographics for Rare Disease Day

Rare Disease Day 2019

Today is #RareDiseaseDay and is an opportunity to highlight some truly unbelievable/frightening statistics around rare diseases.

Cuttsy + Cuttsy

- PMLiVE

Novartis back in the spotlight over Trump/Cohen links

Cohen said the fee intended to get him to work as a lobbyist

- PMLiVE

Streaming Well to “raise the bar in pharma film making”

Company appoints Steve Skinner and Freddie Slaughter to further its goal

Biogen Idec building

FDA starts review of Biogen’s Tecfidera follow-up for MS

It was initally submitted towards the end of 2018 but had been delayed by US gov shutdown

- PMLiVE

Senate grilling makes pharma CEOs squirm, but give little ground

Some signal willingness to compromise, but oppose most radical reforms

Celgene building

FDA begins speedy review of Celgene’s Revlimid combo in lymphoma

R2 met its primary endpoint of PFS in trials

- PMLiVE

AZ says Brilinta hits the mark in diabetic heart disease

The drug can reduce cardiovascular events in diabetics with CAD

- PMLiVE

Pharma industry swamped with no-deal Brexit info, says BIA

Deluge comes just as prime minister hints at delay

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links